ATE507817T1 - Partikel - Google Patents

Partikel

Info

Publication number
ATE507817T1
ATE507817T1 AT06820366T AT06820366T ATE507817T1 AT E507817 T1 ATE507817 T1 AT E507817T1 AT 06820366 T AT06820366 T AT 06820366T AT 06820366 T AT06820366 T AT 06820366T AT E507817 T1 ATE507817 T1 AT E507817T1
Authority
AT
Austria
Prior art keywords
particles
enzyme
cleaved
linkers
linked
Prior art date
Application number
AT06820366T
Other languages
English (en)
Inventor
Molly M Stevens
Rein Ulijn
Sague Anna Laromaine
Liling Koh
Original Assignee
Imp Innovations Ltd
Univ Manchester
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Imp Innovations Ltd, Univ Manchester filed Critical Imp Innovations Ltd
Application granted granted Critical
Publication of ATE507817T1 publication Critical patent/ATE507817T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5115—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6923—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being an inorganic particle, e.g. ceramic particles, silica particles, ferrite or synsorb
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6941—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a granulate or an agglomerate
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nanotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Ceramic Engineering (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Optics & Photonics (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Manufacturing Of Micro-Capsules (AREA)
  • Medicinal Preparation (AREA)
  • Glanulating (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT06820366T 2005-11-29 2006-11-29 Partikel ATE507817T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0524313.4A GB0524313D0 (en) 2005-11-29 2005-11-29 Particles
PCT/GB2006/004459 WO2007063300A2 (en) 2005-11-29 2006-11-29 Particles

Publications (1)

Publication Number Publication Date
ATE507817T1 true ATE507817T1 (de) 2011-05-15

Family

ID=35601447

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06820366T ATE507817T1 (de) 2005-11-29 2006-11-29 Partikel

Country Status (8)

Country Link
US (1) US8318206B2 (de)
EP (1) EP1957038B8 (de)
JP (1) JP5173827B2 (de)
AT (1) ATE507817T1 (de)
DE (1) DE602006021783D1 (de)
ES (1) ES2365536T3 (de)
GB (1) GB0524313D0 (de)
WO (1) WO2007063300A2 (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8168181B2 (en) 2006-02-13 2012-05-01 Alethia Biotherapeutics, Inc. Methods of impairing osteoclast differentiation using antibodies that bind siglec-15
CA2822302A1 (en) 2006-02-13 2007-08-23 Alethia Biotherapeutics Inc. Methods of impairing osteoclast differentiation
GB0618524D0 (en) * 2006-09-20 2006-11-01 Isis Innovation Multimeric particles
JP2010007169A (ja) * 2008-06-30 2010-01-14 Kyushu Univ 金微粒子とその製造方法、およびその用途
WO2010046377A2 (en) * 2008-10-23 2010-04-29 Fundació Privada Institut Català De Nanotecnologia Immunoactivating conjugates comprising nanoparticles coated with peptides
US8673267B2 (en) * 2009-03-02 2014-03-18 Massachusetts Institute Of Technology Methods and products for in vivo enzyme profiling
US20110123452A1 (en) * 2009-11-25 2011-05-26 Nanoprobes, Inc. Metal oligomers and polymers and their use in biology and medicine
GB201004306D0 (en) 2010-03-15 2010-04-28 Imp Innovations Ltd Assay
US20130089739A1 (en) * 2011-10-07 2013-04-11 King Abdullah University of Science and Technology (KAUST) Nanostructured metal oxides and mixed metal oxides, methods of making these nanoparticles, and methods of their use
US8809435B2 (en) 2012-05-16 2014-08-19 The United States Of America As Represented By The Secretary Of The Army Process enhancement via stimuli responsive particle surfaces
CN104684546A (zh) * 2012-06-07 2015-06-03 哈佛大学校长及研究员协会 用于药物靶向的纳米疗法
HK1210192A1 (en) 2012-07-19 2016-04-15 Alethia Biotherapeutics Inc. Anti-siglec-15 antibodies
JP6847660B2 (ja) 2013-06-07 2021-03-24 マサチューセッツ インスティテュート オブ テクノロジー リガンドをコードする合成バイオマーカーのアフィニティベースの検出
EP3149484A1 (de) * 2014-05-30 2017-04-05 IMRA America, Inc. Auf goldnanopartikeln basierender kolorimetrischer diagnosetest zur detektion von proteasen und proteaseinhibitoren
WO2016022547A1 (en) 2014-08-06 2016-02-11 Indiana University Research And Technology Corporation Tuneable delivery of nanoparticle bound active plasmin for the treatment of thrombosis
CA3059358A1 (en) 2017-04-07 2018-10-11 Massachusetts Institute Of Technology Methods to spatially profile protease activity in tissue and sections
CN107843736A (zh) * 2017-09-15 2018-03-27 山东博奥克生物科技有限公司 一种胶体金早孕检测试剂及其制备方法
US12173349B2 (en) 2018-09-25 2024-12-24 Massachusetts Institute Of Technology Lung protease nanosensors and uses thereof
US11835522B2 (en) 2019-01-17 2023-12-05 Massachusetts Institute Of Technology Sensors for detecting and imaging of cancer metastasis
JPWO2024236983A1 (de) * 2023-05-12 2024-11-21

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002320058A1 (en) * 2001-06-06 2002-12-16 The General Hspital Corporation Magnetic-nanoparticle conjugates and methods of use
US7485419B2 (en) * 2004-01-13 2009-02-03 The Board Of Trustees Of The University Of Illinois Biosensors based on directed assembly of particles
AU2005294214A1 (en) * 2004-10-07 2006-04-20 Emory University Multifunctional nanoparticles conjugates and their use

Also Published As

Publication number Publication date
ES2365536T3 (es) 2011-10-06
JP2009517452A (ja) 2009-04-30
US20090181097A1 (en) 2009-07-16
US8318206B2 (en) 2012-11-27
DE602006021783D1 (de) 2011-06-16
EP1957038A2 (de) 2008-08-20
EP1957038B8 (de) 2011-09-21
GB0524313D0 (en) 2006-01-04
WO2007063300A2 (en) 2007-06-07
WO2007063300A3 (en) 2007-10-25
JP5173827B2 (ja) 2013-04-03
EP1957038B1 (de) 2011-05-04

Similar Documents

Publication Publication Date Title
ATE507817T1 (de) Partikel
EA200800952A1 (ru) Конъюгаты антитело-лекарство и способы применения
TR201000668T1 (tr) Neoplasti̇k veya enfeksi̇yoz bozukluklara yöneli̇k i̇mmunoprofi̇laksi̇ veya i̇mmünoterapi̇ i̇çi̇n poli̇pepti̇d-nüklei̇k asi̇t konjugati
MA33892B1 (fr) Anticorps anti-her3, et leurs utilisations
CY1114746T1 (el) Ποτα πρωτεϊνης που εχουν υποστει οξινιση και περιεχουν εναιωρουμενα σωματιδια και μεθοδοι παρασκευης τους
UA106194C2 (ru) Диагностика и лечение рака с применением антитела к ereg
EA200601670A1 (ru) Конъюгаты гидроксиалкилкрахмала и белка
NO20083062L (no) Humane monoklonale antistoffer mot fukosyl-GM1 og fremgangsmater for anvendelse av anti-fukosyl-GM1
CY1113206T1 (el) Μεθοδος παρασκευης προϊοντος συζευξης αντισωματος maytansinoid
WO2007105027A8 (en) Anticancer drugs conjugated to antibody via an enzyme cleavable linker
NO20082240L (no) GLP-2 imitatorstoff, polypeptider, sammensetninger, fremgangsmater og anvendelser
EP1844077A4 (de) Dr5-antikörper und deren verwendung
JO3118B1 (ar) تراكيب وطرق لبروتين c5 المتمم يستهدف الأجسام المضادة
SG144925A1 (en) Methods for treating cardiovascular disease using a soluble ctla4 molecule
NO20091064L (no) Antistoffer mot IL-17A
EA201001625A1 (ru) Человеческие сывороточные альбуминовые линкеры и их конъюгаты
DE602005021072D1 (de) Adzyme und deren verwendungen
WO2008013948A3 (en) Tyrosine phosphorylation sites
WO2008054597A3 (en) Tyrosine phosphorylation sites
WO2008013934A8 (en) Tyrosine phosphorylation sites
ATE497976T1 (de) Spezifisch an vygfvracl-hla-a24 bindende t-zellen-rezeptoren
EA200702193A1 (ru) Гликозилирование белков
CY1110891T1 (el) Παραγωγα 6-ετεροαρυλπυριδοϊνδολονης, η παρασκευη τους και η εφαρμογη τους στη θεραπευτικη αγωγη
ATE556071T1 (de) Kappa-opioidrezeptor-liganden
WO2006078648A3 (en) Rhinovirus vaccines

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties